Studies show vaccine produces robust antibody responses in school-age children, companies say
The Pfizer and BioNTech pharmaceutical partnership announced on Wednesday that their Covid-19 vaccine was safe, effective and produced robust antibody responses in 12-to 15-year old children, paving the way for them to seek US authorisation within the next few weeks and from regulators in other countries swiftly thereafter.
Related: Germany restricts use of AstraZeneca jab to over-60s
